What’s Hot and What’s Not in IO 2021?

Oncology venture funding, IPOs and partnerships have been exceptionally high in deal volume and values. Cancer continues to be the leading therapeutic area in the number and size of early deals, and the oncology pipeline continues to be a rich source of both follow-on agents as well as first-in-class programs. Immuno-oncology leads in deal values, but much of the pipeline is in tumor-targeted therapies with ever greater patient selection strategies (precision oncology). Targets for adoptive cell therapy (ACT) and next-gen biologics include validated targets (HER2, for example) but also up-and-coming targets like TROP2 and novel targets.   

In immuno-oncology, potential partners are pursuing next-generation checkpoint inhibitors and costimulatory agents, from the BIOND-Sanofi partnership around ILT2 to ImCheck’s various BTN programs. Investors are funding a diverse range of cell types and sources. And finally, a new frontier of endogenous reprogramming has opened up where synthetic biology intersects with RNA and gene therapy/editing, along with cell redirecting approaches and drug delivery.

In the on-demand webinar, key biotech and pharma stakeholders discuss the opportunities and challenges in funding, deals, clinical development, and commercialization.  

SEE THE
REPLAY


ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.

SPEAKERS:


Company team

Linda Pullan, PhD - Moderator

Pullan Consulting

Linda and her team at Pullan Consulting offer biotech and pharmaceutical companies consulting in all aspects of partnering. Linda has a PhD in Biochemistry, a BS in Chemistry, and over twenty years of drug industry experience, including work on more than 75 deals. Learn more...

Company team

Jeffrey M. Bockman, PhD 

EVP, Oncology Practice Head, Cello Health BioConsulting

Jeff leads the Oncology and Virology Practices at Cello Health BioConsulting (Previously Defined Health). He received a BA from the University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University. Learn more...

Company team

Paul Frohna, MD, PhD

Chief Medical Officer, ImCheck

Dr. Paul Frohna is a physician-scientist with over 20 years of experience in the biotech industry with expertise in translational medicine, clinical trial design, and clinical and regulatory strategy. Learn more...

Company team

Jacob Becraft, PhD

CEO, Co-founder, Strand Therapeutics Inc

Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Learn more...

Company team

Asthika Goonewardenes

Managing Director, Equity Research — BiotechTruist Securities

Asthika Goonewardene is a Managing Director at Truist Securities covering biotechnology companies with a focus on cell therapy, immuno-oncology, and antibody technology. Prior to joining the STRH Biotech team in 2019, Mr Goonewardene was a senior analyst with Bloomberg Intelligence, leading coverage of the global biotech sector. Learn more...

Company team

Andrew Pierce

VP of Translational Biology, Crescendo Biologics

Andrew Pierce has spent eighteen years directing and mentoring teams of PhDs and associates translating science into clinical oncology drug development: 10 in industry and 8 in academia. Aligning targeted drugs and combinations to optimal clinical settings and individual patients. Andrew has International leadership for both large and small molecules. Learn more...